Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy

• Published in: Revue neurologique Vol. 177; no. 10; pp. 1241 - 1249
• Main Authors: Guery, D., Marignier, R., Durand-Dubief, F., Lavie, C., Pique, J., Guerrier, O., Vukusic, S.
• Format: Journal Article
• Language: English
• Published: Elsevier Masson SAS 01.12.2021
• Subjects: Inefficacy; Multiple sclerosis; Natalizumab; Progressive multifocal leukoencephalopathy; EDMUS; Multiple sclerosis; Natalizumab; MOG; MS; AQP4; MOGAD; NMOSD; PML; Progressive multifocal leukoencephalopathy; Inefficacy; JCV; OFSEP; SDMT; EDSS

•Natalizumab is an effective treatment of MS, with few failures (13% in our study).•Every failure needs investigation with a limited number of etiologies to consider.•PML, anti-natalizumab antibodies, neuromyelitis optica spectrum disorder (NMOSD) have to be considered in case of inefficacy. Nataliz...